Medications development to treat alcohol dependence: a vision for the next decade. - Test2 - elhamkhani - TriplyDB

Medications development to treat alcohol dependence: a vision for the next decade.

Medications development to treat alcohol dependence: a vision for the next decade.

http://www.wikidata.org/entity/Q36357552

about

Multidisciplinary View of Alcohol Use Disorder: From a Psychiatric Illness to a Major Liver Disease Alcohol liver disease: A review of current therapeutic approaches to achieve long-term abstinence The development of acamprosate as a treatment against alcohol relapse Recommendations for the Design and Analysis of Treatment Trials for Alcohol Use Disorders P2X4 receptors (P2X4Rs) represent a novel target for the development of drugs to prevent and/or treat alcohol use disorders The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study.A Genetic Animal Model of Alcoholism for Screening Medications to Treat Addiction.Nicotinic receptor modulation to treat alcohol and drug dependence Acamprosate produces its anti-relapse effects via calcium A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence Animal models for medications development targeting alcohol abuse using selectively bred rat lines: neurobiological and pharmacological validity Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence.Contribution of P2X4 receptors to ethanol intake in male C57BL/6 mice.Transdermal delivery of cannabidiol attenuates binge alcohol-induced neurodegeneration in a rodent model of an alcohol use disorder.Multiday administration of ivermectin is effective in reducing alcohol intake in mice at doses shown to be safe in humans Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature Avermectins differentially affect ethanol intake and receptor function: implications for developing new therapeutics for alcohol use disorders.Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial.Glycine and GABA(A) ultra-sensitive ethanol receptors as novel tools for alcohol and brain research.Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings.Social network moderators of naltrexone and behavioral treatment effects on heavy drinking in the COMBINE study.Clinical impact of alcohol-related cirrhosis in the next decade: estimates based on current epidemiological trends in the United States.Recruitment techniques for alcohol pharmacotherapy clinical trials: A cost-benefit analysis Recent Advances in Nicotinic Receptor Signaling in Alcohol Abuse and Alcoholism.The diminished pipeline for medications to treat mental health and substance use disorders Pharmacotherapy for alcohol use disorder: current and emerging therapies 11β-hydroxysteroid dehydrogenase inhibition as a new potential therapeutic target for alcohol abuse Sex and the Lab: An Alcohol-Focused Commentary on the NIH Initiative to Balance Sex in Cell and Animal Studies.Substance use disorders: psychoneuroimmunological mechanisms and new targets for therapy.Preclinical Medication Development: New Targets and New Drugs.Discovery, Development, and Adoption of Medications to Treat Alcohol Use Disorder: Goals for the Phases of Medications Development A Pilot Study of the Safety and Initial Efficacy of Ivermectin for the Treatment of Alcohol Use Disorder.Crosswalk between DSM-IV dependence and DSM-5 substance use disorders for opioids, cannabis, cocaine and alcohol.Jobelyn® Supplement Lowered Neuronal Degeneration: Significance of Altered p53 and ɤ-Enolase Protein Expressions in Prefrontal Cortex of Rat Exposed to Ethanol.The importance of animals in advancing research on alcohol use disorders.The effects of varenicline on alcohol seeking and self-administration in baboons.Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III.The transition to medication adoption in publicly funded substance use disorder treatment programs: organizational structure, culture, and resources.Research opportunities for medications to treat alcohol dependence: addressing stakeholders' needs.Current pharmacological treatment approaches for alcohol dependence.

P2860

Q26771090-AC2C38AE-600C-4E5C-ABCF-0CCA1F340346 Q26801196-3713DABB-4A0C-48A8-96B3-AC166445A4B8 Q26862199-BF1B1CE4-EABD-4DF9-88A0-BD3756D2606A Q27013929-2F714B5E-2AC4-4F39-948F-713AD0BF4828 Q27021285-F26AB70F-ACF8-4DAC-9A94-7079AF4301C5 Q27310644-72F00050-C4DC-4AFD-A446-64D6E6DBD7AE Q28068256-1C5F6612-21AF-4102-A981-5D43FB325EFA Q28087047-D8F1F799-F0D2-46F8-A9CD-B122AE2A7CEF Q28299533-E6FB6EB1-4A58-40AA-B6FB-E1009708BAB8 Q30412161-D5CF1BC3-EABA-4B16-82CF-C98A99DBF37A Q30447847-5B8B8F67-6B49-40BD-A8A2-3314B66D01C3 Q33594729-B5C5F366-8463-42AA-BEAF-A2A46BECC375 Q33649945-48556AEC-F810-4FE1-AEB3-333CA41CC435 Q33897251-1A89E362-B1D9-4A87-BE07-4C9FFA3BA860 Q34018603-9A1D1406-E421-4277-BABB-905F30D46C82 Q34181746-1F945C75-3CC0-4909-A277-A375723E6493 Q34407070-4B29765F-A269-446E-B8DE-0BFD0FA036B7 Q34549370-6116727B-ED9A-4461-B07C-03DF46D43F30 Q34573962-FFF574AC-630E-4DCF-BD9A-97C9F8A2777A Q35195302-E4FED382-6120-4473-B370-E878FE7CCACC Q35565599-925ACFDE-AF0A-4256-8DDE-24F501433A72 Q36219877-69896536-1064-4141-A27E-FD8FDA2F25E3 Q36440595-53E42D9B-6D21-4AF8-8CC0-DA990AED3377 Q36581617-92958A47-2F8E-48F8-B45A-8788843B49A5 Q36677600-CFC6BA88-D02A-4630-B203-61556E22632C Q36684437-C4DDE75A-7E41-44BE-BFD8-0A14C97F7077 Q36915489-EF8C64B4-C889-4ABD-989A-0905B6034251 Q36957936-F9AB008C-4F1A-42D6-8E3F-FABBBCDFFFE0 Q37052393-7FA66703-0C4A-4F7C-924E-C3019DB40F7A Q37059156-60164A9F-B56A-4E67-8794-98FEAF15CBBF Q37059221-272ADBA7-DC40-4ECB-9ED5-F0001B16651D Q37088573-9BE93A6C-0898-4667-9D3A-ECF266B23EA4 Q37107238-49490516-7321-49B5-B6C1-D01F0A753D4C Q37298409-0C1B8A5F-62B3-4A64-9AA3-35FC6D998F2F Q37313771-DF4D12D4-418E-4065-94E7-E2FF494DCB6B Q37404736-F7753472-117C-491A-AAA8-EC7F4D68C517 Q37589721-D6D0C8CD-B61E-403D-AFF9-323A1DF3A16C Q37729027-9B2AAB6E-53C4-4BC0-92C1-53E9FA287083 Q38124358-EDE76B95-B3A6-43A4-A187-90DB1BC6546F Q38181213-7A8D8072-1ABA-4708-9034-06E2FFD26B3F

P2860

Medications development to treat alcohol dependence: a vision for the next decade.

http://www.wikidata.org/entity/Q36357552

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Medications development to treat alcohol dependence: a vision for the next decade.

@ast

Medications development to treat alcohol dependence: a vision for the next decade.

@en

type

label

Medications development to treat alcohol dependence: a vision for the next decade.

@ast

Medications development to treat alcohol dependence: a vision for the next decade.

@en

prefLabel

Medications development to treat alcohol dependence: a vision for the next decade.

@ast

Medications development to treat alcohol dependence: a vision for the next decade.

@en

P1433

Q36357552-3566D178-1EF7-435D-9EC0-3438A4CD8893

P1476

Q36357552-46F1CA5B-6DEA-43A0-90EC-BBA6ACBA00D1

P2093

Q36357552-19B271CF-6BFE-42A4-9011-DD050BDA0280

Q36357552-34382611-986E-41DC-82C2-0BB2C21124B8

Q36357552-3B88A849-BB55-410D-9B8B-3EB708248BE6

Q36357552-63F1DA3B-F54E-4809-848E-4AA5D67FA6F4

Q36357552-8B10CC04-DBB1-492B-8DF8-E5A389F92CFC

Q36357552-8B64070D-4800-4C0D-8C85-56CC4886990C

Q36357552-C4F54D0C-E56F-4716-BB8F-FBD5D8D5CB31

Q36357552-E0347D25-A292-4E34-8BDC-A44307F3C889

Q36357552-EB2B0E2F-7CA9-47A0-88DE-A81B9C506B20

P2860

Q36357552-0054E50D-B340-43DA-AEF4-2022824CFAD7

Q36357552-02B91965-6391-4DFC-B02E-88F9D9D5A0DA

Q36357552-09AC13AA-835B-406C-A298-83E684C75AF4

Q36357552-102BC98A-3ED4-4A07-A2D4-88702F1C5F0B

Q36357552-10888356-85A9-43DA-B4FD-A0C2E9CD0621

Q36357552-13BC6CB9-11FA-4B39-A829-AC7EA8D6CAC2

Q36357552-144CEB5B-288B-4251-B943-B2CD2B86C831

Q36357552-152BF03B-2D71-4EE4-B018-33BD0ACB0276

Q36357552-1693E5B6-3E1F-44B3-BE2C-E57B029A686C

Q36357552-23522C2C-F47E-4B7C-8982-45D6145E4C7A

P304

Q36357552-9FE547B2-287C-4A1A-88F3-B817776D86A0

P31

Q36357552-02F628B5-20B6-44F6-9F63-C412EC4E4BF7

P356

Q36357552-6E8E53DE-01DF-4B52-B4B1-ED19AF6CC56D

P433

Q36357552-7A1BB8A8-7201-4191-A501-C2CD1D9E3078

P478

Q36357552-285E679B-3144-45FE-AC68-CBCB7D226539

P50

Q36357552-78440AF2-4F60-4B8E-A03B-FA5A7D965F5B

P577

Q36357552-C12C8FA2-8464-41E6-80C5-D2277871BA59

P5875

Q36357552-B48C525E-96DF-4650-92D3-87A38E784421

P698

Q36357552-831EA7E5-7A3A-4935-9383-C70C3FB16566

P932

Q36357552-62E205A0-5B0B-4090-A83F-5A666568081E

P356

J.1369-1600.2012.00454.X

P1433

Addiction Biology

P1476

Medications development to treat alcohol dependence: a vision for the next decade.

@en

P2093

Antonio Noronha

http://www.w3.org/2001/XMLSchema#string

Changhai Cui

http://www.w3.org/2001/XMLSchema#string

Daniel E Falk

http://www.w3.org/2001/XMLSchema#string

Howard Moss

http://www.w3.org/2001/XMLSchema#string

Joanne B Fertig

http://www.w3.org/2001/XMLSchema#string

Mark Egli

http://www.w3.org/2001/XMLSchema#string

Megan L Ryan

http://www.w3.org/2001/XMLSchema#string

Raye Z Litten

http://www.w3.org/2001/XMLSchema#string

Robert Huebner

http://www.w3.org/2001/XMLSchema#string

P2860

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

Alcoholism: A Systems Approach From Molecular Physiology to Addictive Behavior

Actual Causes of Death in the United States, 2000

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

Involvement of the atrial natriuretic peptide transcription factor GATA4 in alcohol dependence, relapse risk and treatment response to acamprosate

Acute withdrawal, protracted abstinence and negative affect in alcoholism: are they linked?

Neurocircuitry of addiction

A prospective study of risk drinking: at risk for what?

Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome

Medications for unhealthy alcohol use: across the spectrum.

P304

513-527

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1369-1600.2012.00454.X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-03-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

223994972

http://www.w3.org/2001/XMLSchema#string

P698

22458728

http://www.w3.org/2001/XMLSchema#string

P932

3484365

http://www.w3.org/2001/XMLSchema#string